研报掘金丨国海证券：隆培素上市在即，期待TransCon技术长效生长激素商业化空间，建议近期重点关注维昇药业

Core Viewpoint - Guohai Securities reports that the long-acting growth hormone, Lonpei, based on TransCon technology, is expected to be launched soon, demonstrating superior efficacy and equivalent safety compared to short-acting growth hormones [1] Company Summary - Lonpei growth hormone was introduced by Weisheng Pharmaceutical in November 2018 through a licensing agreement with Ascendis Pharma [1] - The growth hormone utilizes TransCon (transient conjugation technology) for long-acting delivery, making it the only long-acting growth hormone that continuously releases unmodified human growth hormone between weekly doses [1] - Completed Phase III pivotal trials in China have validated that Lonpei is the only long-acting growth hormone showing superior efficacy and equivalent safety in comparison to short-acting growth hormones in positive drug control and parallel group trials [1] - Weisheng Pharmaceutical anticipates that Lonpei will receive domestic approval for marketing in the fourth quarter of 2025, suggesting that investors should closely monitor the company in the near term [1]